EISAI ( EISAI)

Primary tabs

EISAI's picture

Management

Contact Address

About EISAI

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research.

EISAI press release, blog etc

Tue, 08/27/2024 - 16:25 RELEASE OF INSOMNIA AWARENESS VIDEO FOR JAPANS AUTUMN SLEEP HEALTH WEEKS
Fri, 07/26/2024 - 05:28 Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
Mon, 07/15/2024 - 23:16 EISAI ENTERS INTO LICENSE AGREEMENT FOR FOSRAVUCONAZOLE IN ASIA/OCEANIA WITH SATO PHARMA
Thu, 05/23/2024 - 01:28 METOJECT SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR LAUNCHED IN JAPAN
Mon, 05/13/2024 - 13:59 ANTIEPILEPTIC DRUG FYCOMPA APPROVED IN CHINA FOR ADJUNCTIVE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
Wed, 02/21/2024 - 01:15 EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION,AIMING TO ACHIEVE NET ZERO BY 2050
Tue, 02/20/2024 - 09:37 EISAI SELECTED FOR HUMAN CAPITAL LEADERS 2023 AND HUMAN CAPITAL MANAGEMENT GOLD QUALITY, RECOGNIZED AS COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES
Fri, 02/16/2024 - 19:15 METOJECT SUBCUTANEOUS INJECTION PEN (METHOTREXATE) PEN-TYPE AUTOINJECTOR APPROVED IN JAPAN
Thu, 02/01/2024 - 11:33 EISAI COMMENCES FULLY-FLEDGED BUSINESS ACTIVITIES AT PHARMA SALES SUBSIDIARY IN SOUTH AFRICA
Fri, 01/19/2024 - 13:55 EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE EIGHTH TIME
Mon, 12/19/2022 - 19:41 EISAI TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA (perampanel) CIII IN UNITED STATES TO CATALYST PHARMACEUTICALS
Wed, 09/21/2022 - 01:59 RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY
Sun, 09/11/2022 - 23:05 Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Mon, 09/05/2022 - 22:26 Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Wed, 06/22/2022 - 00:23 EISAIS NOUKNOW, DIGITAL TOOL FOR SELF-ASSESSMENT OF BRAIN PERFORMANCE, IS TO UTILIZE FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2022 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
Thu, 06/02/2022 - 20:55 EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
Mon, 05/09/2022 - 18:45 EISAI INITIATES PREPARATION FOR NEW DRUG APPLICATION, BASED ON THE RESULTS OF AN INVESTIGATOR-INITIATED CLINICAL TRIAL OF ULTRAHIGH-DOSE MECOBALAMIN FOR AMYOTROPHIC LATERAL SCLEROSIS IN JAPAN
Mon, 03/28/2022 - 04:04 Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies
more

InfoBox

HomePagewww.eisai.com
LinkedInwww.linkedin.com/company/eisai
Wikipediaen.wikipedia.org/wiki/Eisai_(company)